HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 24, No 12, December 2019 – Precision Medicine for Brain Tumours       » First Alzheimer's drug to be approved in 17 years holds promise for treatment       » Tencent make medical information readily available to the public       » United States FDA approves first China-made cancer drug       » Value-Based Healthcare: A Paradigm Shift for Better Patient Outcomes       » Precision Agriculture for Future Nutritional Needs      
EYE ON CHINA
Proposed law change to increase penalties for drug violations
Violations such as making or selling fake drugs could see companies lose their business licenses

The penalties for companies that produce or sell fake or substandard pharmaceuticals in China are to be increased, according to a draft amendment to the country's Drug Management Law.

Manufacturers that operate without the required permit will face fines up to 30 times the value of their products. Under the current law, the maximum fine is five times the value.

The proposed amendment, now under review by the National People's Congress Standing Committee, the top legislature, states that violations such as making or selling fake drugs could see companies lose their business license.

Business executives and drug supervision officials will also face heavier punishment in cases involving pharmaceuticals, while supervision of certain drugs, such as vaccines, will be intensified to ensure safety and quality.

Jiao Hong, head of the National Medical Products Administration, said the draft aims to improve supervision of drugs following the vaccine scandal at Changchun Changsheng Biotech, a major vaccine producer in Jilin province.

The administration fined the company 9.1 billion yuan ($1.3 billion) for fabricating production records and using expired materials to manufacture a human rabies vaccine.

Source: China Daily

Click here for the complete issue.

NEWS CRUNCH  
news Technology giant, Tencent Holdings Limited, promotes medical science and healthcare
news ECV2019 China Healthcare and Pharma Digital Innovation Summit Held Successfully in Shanghai — The "Highway" Era of Healthcare Digital Transformation
news Natural Extracts Innovated, Transformed and Diversely Laid Out to Embrace the Blue Ocean Market of Big Health
news The Proteona Oncology Challenge using ESCAPETM Single Cell Proteogenomic Analysis
PR NEWSWIRE  
Asia Pacific Biotech News
SPOTLIGHT  
LIFE OF A SCIENTIST  

APBN Editorial Calendar 2019
January:
Taiwan Medical tourism
February:
Marijuana as medicine — Legal marijuana will open up scientific research
March:
Driven by curiosity
April:
Career developments for researchers
May:
What's cracking — Antibodies in ostrich eggs
June:
Clinical trials — What's in a name?
July:
Traditional Chinese medicine in modern healthcare — Integrating both worlds
August:
Digitalization vs Digitization — Exploring Emerging Trends in Healthcare
September:
Healthy Ageing — How Science is chipping in
October:
Disruptive Urban Farming — Microbes, Plasmids, and Recycling
November:
Evaluating cost effectiveness of genomic profiling
December:
Precision Medicine for Brain Tumours
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Deborah Seah
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2019 World Scientific Publishing Co Pte Ltd  •  Privacy Policy